BR112013005278A2 - produtos vasculares acelulares - Google Patents

produtos vasculares acelulares

Info

Publication number
BR112013005278A2
BR112013005278A2 BR112013005278A BR112013005278A BR112013005278A2 BR 112013005278 A2 BR112013005278 A2 BR 112013005278A2 BR 112013005278 A BR112013005278 A BR 112013005278A BR 112013005278 A BR112013005278 A BR 112013005278A BR 112013005278 A2 BR112013005278 A2 BR 112013005278A2
Authority
BR
Brazil
Prior art keywords
products
acellular
tissue matrix
vascular tissue
vascular
Prior art date
Application number
BR112013005278A
Other languages
English (en)
Other versions
BR112013005278B1 (pt
Inventor
Eileen Ingham
John Fisher
Stacy-Paul Wilshaw
Original Assignee
Univ Leeds
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1016150.3A external-priority patent/GB201016150D0/en
Priority claimed from GBGB1020846.0A external-priority patent/GB201020846D0/en
Application filed by Univ Leeds filed Critical Univ Leeds
Publication of BR112013005278A2 publication Critical patent/BR112013005278A2/pt
Publication of BR112013005278B1 publication Critical patent/BR112013005278B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3625—Vascular tissue, e.g. heart valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3695—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the function or physical properties of the final product, where no specific conditions are defined to achieve this
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Battery Electrode And Active Subsutance (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

produtos vasculares acelulares. a presente invenção refere-se a um produto que compreende uma matriz de tecido vascular xenogênico acelular natural que possui pelo menos 80% de redução no conteúdo de dna, em comparação com uma matriz de tecido vascular de controle não tratada e sendo antigenicamente inerte por estar substancialmente livre de epitopos capazes de reagir com os anticorpos humanos pré-formados e também sem ter a capacidade de ativar o complemento substancialmente. a invenção também inclui métodos de preparação de tais produtos e utilizaçoes dos produtos, especialmente em cirurgia de bypass.
BR112013005278-3A 2010-09-27 2011-09-26 Produtos que comprendem matriz de tecido vascular xenogênico acelular e método de preparação de um tecido vascular xenogênico acelular BR112013005278B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1016150.3 2010-09-27
GBGB1016150.3A GB201016150D0 (en) 2010-09-27 2010-09-27 Acellular vascular products
GB1020846.0 2010-12-09
GBGB1020846.0A GB201020846D0 (en) 2010-12-09 2010-12-09 Acellular vascular products
PCT/GB2011/051817 WO2012042250A1 (en) 2010-09-27 2011-09-26 Acellular vascular products

Publications (2)

Publication Number Publication Date
BR112013005278A2 true BR112013005278A2 (pt) 2016-05-17
BR112013005278B1 BR112013005278B1 (pt) 2019-07-09

Family

ID=45892022

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013005278-3A BR112013005278B1 (pt) 2010-09-27 2011-09-26 Produtos que comprendem matriz de tecido vascular xenogênico acelular e método de preparação de um tecido vascular xenogênico acelular

Country Status (11)

Country Link
US (1) US9510933B2 (pt)
EP (1) EP2621548B1 (pt)
JP (1) JP5881711B2 (pt)
CN (1) CN103124570B (pt)
AU (2) AU2011309900B2 (pt)
BR (1) BR112013005278B1 (pt)
CA (1) CA2808478C (pt)
ES (1) ES2628441T3 (pt)
HK (1) HK1185292A1 (pt)
PL (1) PL2621548T3 (pt)
WO (1) WO2012042250A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10058630B2 (en) * 2012-10-22 2018-08-28 Concievalve, Llc Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
US10213526B2 (en) 2014-03-21 2019-02-26 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods for preparation of a terminally sterilized hydrogel derived from extracellular matrix
AU2017207015B2 (en) 2016-01-13 2022-08-04 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Vascular extracellular matrix hydrogel
CN113425912A (zh) * 2020-03-23 2021-09-24 成都中科奥格生物科技有限公司 一种脱细胞真皮材料及其制备方法和用途
CN113368306A (zh) * 2020-03-23 2021-09-10 成都中科奥格生物科技有限公司 低免疫原性生物材料及其制备方法和用途
CN113425905A (zh) * 2020-03-23 2021-09-24 成都中科奥格生物科技有限公司 一种血管材料及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8618374D0 (en) * 1986-07-28 1986-09-03 Hsc Res Dev Corp Biological vascular prostheses
US20040208842A1 (en) * 2001-09-18 2004-10-21 Ritchie Branson W. Antimicrobial cleansing compositions and methods of use
GB2375771A (en) 2001-05-24 2002-11-27 Univ Leeds Decellularisation of tissue implant material
EP1517715A2 (en) 2002-06-28 2005-03-30 Cardio, Inc. Decellularized tissue
KR20070002057A (ko) * 2004-03-17 2007-01-04 레비비코르 인코포레이션 기능성 알파 1,3 갈락토실트랜스펙션스페라제의 어떠한발현도 결여된 동물로부터 유래된 조직 산물
US20050266390A1 (en) * 2004-06-01 2005-12-01 Yuichiro Ueda Processes for removing cells and cell debris from tissue and tissue constructs used in transplantation and tissue reconstruction
EP1869082B1 (en) 2005-03-04 2011-04-13 The Board Of Trustees Of The University Of Illinois Coagulation and fibrinolytic cascades modulator
PL2094325T3 (pl) * 2006-11-16 2012-03-30 Tissue Regenix Ltd Przygotowanie tkanki do przeszczepu łąkotki
GB0622846D0 (en) 2006-11-16 2006-12-27 Univ Leeds Preparation of tissue for meniscal implantation
US20080306610A1 (en) * 2007-06-07 2008-12-11 Zimmer Orthobiologics, Inc. Tissue processing for nonimmunogenic implants
WO2009009620A2 (en) * 2007-07-10 2009-01-15 Lifecell Corporation Acellular tissue matrix compositions for tissue repair
CN100594041C (zh) * 2007-12-27 2010-03-17 南京医科大学附属南京儿童医院 猪血管脱细胞的支架的化学与物理结合的制备方法
US8735054B1 (en) * 2008-01-04 2014-05-27 Lifecell Corporation Acellular tissue matrix preservation solution
CN101474426B (zh) 2009-01-14 2012-09-05 首都医科大学宣武医院 一种脱除血管组织内细胞的血管基质及其制备方法
EP3545980A1 (en) * 2010-02-26 2019-10-02 DeCell Technologies Inc. Methods for tissue decellularization

Also Published As

Publication number Publication date
JP2013537828A (ja) 2013-10-07
CN103124570A (zh) 2013-05-29
ES2628441T3 (es) 2017-08-02
EP2621548B1 (en) 2017-05-24
AU2014203460A1 (en) 2014-07-17
JP5881711B2 (ja) 2016-03-09
AU2011309900A1 (en) 2013-05-02
CA2808478C (en) 2015-10-06
US20130197667A1 (en) 2013-08-01
CN103124570B (zh) 2015-04-22
US9510933B2 (en) 2016-12-06
EP2621548A1 (en) 2013-08-07
AU2014203460B2 (en) 2016-04-14
PL2621548T3 (pl) 2017-11-30
HK1185292A1 (en) 2014-02-14
AU2011309900B2 (en) 2014-07-24
CA2808478A1 (en) 2012-04-05
WO2012042250A1 (en) 2012-04-05
BR112013005278B1 (pt) 2019-07-09

Similar Documents

Publication Publication Date Title
BR112013005278A2 (pt) produtos vasculares acelulares
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2010005018A (es) Tratamiento de complicaciones de nacimiento prematuro.
MX2013011835A (es) Composiciones nutricionales que incluyen acidos grasos de cadena ramificada para la curacion de heridas.
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
BR112012028290A2 (pt) desintoxicação de acetato derivado de biomassa via conversão metabólica em etanol, acetona, isopropanol ou acetato de etila
BR112015009473A2 (pt) hidrolisado de colágeno e uso do mesmo
BR112013005679A2 (pt) imidazopiridazinas substituídas
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
BR112016010175A2 (pt) Repressor genético, seus usos, e composição farmacêutica
PH12016500478A1 (en) Isolated strain of clonostachys rosea for use as a biological control agent
EA201490512A1 (ru) Композиции, содержащие культивируемую в анаэробных условиях микробиоту кишечника человека
BR112012017690A2 (pt) Emulsões nutricionais compreendendo hmb de cálcio
WO2013039861A3 (en) Engineered nucleic acids and methods of use thereof
BR112016029713A8 (pt) uso de uma carboximetilcelulose reticulada e uso de um agente gelificante
NZ595952A (en) Antimicrobial compositions and related methods of use
NZ590343A (en) Compositions monovalent for cd28 binding and methods of use
WO2012163869A3 (en) Composition comprising an alkoxysilane and a modified starch, and cosmetic use thereof
BR112015017069A2 (pt) processo para preparação de extrato a partir de meio de cultura de ceriporialacerata e composições farmacêuticas preparadas pelo que para prevenção ou tratamento de doenças diabéticas e complicações diabéticas, que contêm extrato de meio de cultura de ceriporialacerata como ingrediente ativo
EA201390826A1 (ru) ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA
MX2013012661A (es) Compuestos de piridazina biciclicos como inhibidores pim.
BR112017012682A2 (pt) processo para aperfeiçoamento de porções de músculo e produtos
WO2012028335A3 (en) Kinases as targets for anti-diabetic therapy
MY178445A (en) Novel antibody binding to tfpi and composition comprising the same
NZ602317A (en) Stabilized alpha-galactosidase and uses thereof

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: TISSUE REGENIX LIMITED (GB)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/09/2011, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/09/2011, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 10A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2640 DE 10-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.